Key Companies Covered in the Global Zellweger Spectrum Disorder Market Research Report by Research Nester are Invitae Corporations, CENTOGENE N.V., GeneDX, LLC, Blueprint Genetics Oy, Siemens Healthcare Gmbh, Carestream Health, Inc., Agfa-Gevaert Group, Shimadzu Corporation, Asper Biogene LLC, Trivitron Healthcare, and other key market players.
New York, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Research Nester has published a detailed market report on ‘Global Zellweger Spectrum Disorder Market’ for the forecast period, i.e. 2022 – 2031 which includes the following factors:
Market growth over the forecast period
Key market players and their detailed profiling
Global Zellweger Spectrum Disorder Market Size:
The global Zellweger spectrum disorder market is estimated to grow at a CAGR of ~6% over the forecast period. Peroxisome biogenesis disorders (PBDs), also known as Zellweger spectrum, are rare conditions that are characterized by the body's inability to produce peroxisomes. The 13 PEX genes, which are crucial for the healthy development and operation of peroxisomes, any defect in these genes are the cause of this disease. The growth of the market can be ascribed to the increasing prevalence of the Zellweger spectrum (ZS) disorder in the new borns. It is believed that the PEX1 gene has a mutation that causes ZS in the majority of instances and they affect nearly 1 in 50,000 to 1 in 75,000 babies, along with the other disorders on the Zellweger spectrum. Further, the market for Zellweger spectrum disorders is anticipated to grow over the course of the projected period owing to the increasing screening tests, sophisticated diagnostics for the condition, and rising governments’ attempts to raise public awareness of rare diseases. It was observed that approximately USD 997 billion is spent on the prevention, diagnosis, treatment, and awareness of rare diseases, of which USD 449 billion goes directly toward medical expenses and around USD 437 billion accounted for indirect medical costs.
Get a Sample PDF Brochure: https://www.researchnester.com/sample-request-4087
Global Zellweger Spectrum Disorder Market: Key Takeaways
European region gains a significant portion of the revenue
Genetic tests segment to gain a substantial share of the revenue graph
Hospitals sub-segment remains prominent in the end-user segment
Increasing Research on Rare Diseases and Growing Spending on Research to Boost Market Growth
ZSD was a rare illness about which little was known. However, because of increasing research spending, clinical knowledge is now improving. This is anticipated to encourage early diagnosis of the condition and is expected to aid in developing suitable treatment strategies. In the end, growth in the global market is estimated to have resulted from all of these factors. For instance, investment in medical and health research and development (R&D) in the United States (U.S.) increased by 11% to around USD245 billion in 2020 from 2019.
In addition to this, healthcare professionals are increasingly interested in conducting aggressive research to find solutions for previously understudied and uncommon diseases including Zellweger spectrum disorder as they want to be fully ready for any comparable occurrence in the future as the chances of developing diseases in children are increasing. It was noticed that children have a 50% probability of carrying the mutant gene if both parents do. The mutated genes are inherited by a carrier, who doesn't have the illness. The possibility of the disease-transmitting to the kids is 25%. Moreover, there is no known cure for the illness, however, treatments help lessen its symptoms. During the projection period, there is expected to be significant growth in the global market for Zellweger spectrum disorders owing to the ease of access to sophisticated diagnostic tools, natural history research, and improving electronic health records.
For more information in the analysis of this report, visit: https://www.researchnester.com/reports/zellweger-spectrum-disorder-market/4087
Global Zellweger Spectrum Disorder Market: Regional Overview
The global Zellweger spectrum disorder market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa region.
Impeccable Research and Healthcare Infrastructure to Drive Growth in the North America Region
The market in North America region is estimated to witness noteworthy growth over the forecast period owing to impeccable research and healthcare infrastructure. There is a system for newborn screening tests, which results in the accessibility of highly advanced diagnostic tools. Additionally, the increasing spending on research and development in the region is predicted to drive market growth during the forecast period. The World Bank reports that in 2020, R&D expenditures in North America totaled 3.32% of its GDP.
Increasing Healthcare Spending to Drive Growth in the Europe Region
On the other hand, the market in the Europe region is expected to grow significantly over the forecast period owing to the increasing efforts for the diagnosis and treatment of the condition. The market for Zellweger spectrum disorders is anticipated to experience considerable expansion in the region during the forecast period as a result of growing clinician vigilance, parental genetic counseling, and increasing healthcare spending. For instance, in 2020, general government spending on health in the EU reached to USD 1 074 billion, or 8.0% of GDP.
Get a Sample PDF of Zellweger Spectrum Disorder Market Report@ https://www.researchnester.com/sample-request-4087
The study further incorporates Y-O-Y growth, demand & supply and forecast future opportunity in:
North America (U.S., Canada)
Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe)
Latin America (Brazil, Mexico, Argentina, Rest of Latin America)
Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific)
Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
Global Zellweger Spectrum Disorder Market, Segmentation by End-User
Out of these, the hospital segment is estimated to hold notable market share over the forecast period owing to rising patient flow in the hospitals. Further, the global market for Zellweger spectrum disorders is anticipated to expand throughout the projected period owing to the increasing spending on healthcare across the globe as a result of doctors' increasing caution and suggestions of tests for the parents. As per the health expenditure report, global health spending has increased overall during the previous 20 years, doubling in real terms, reaching USD 8.5 trillion in 2019 and 9.8% of GDP (up from 8.5% in 2000).
For more insights on the market share of various regions: https://www.researchnester.com/sample-request-4087
Global Zellweger Spectrum Disorder Market, Segmentation by Diagnosis
Among these, the genetic tests segment is estimated to gain substantial market share over the forecast period as genetic tests look for alterations in DNA, often known as mutations or variations. The medical care a member receives can alter as a result of genetic testing, which has various applications in medicine. In fact, genetic testing helps diagnose a genetic disorder including ZSD, or reveals the risk of contracting rare diseases. Moreover, the higher cost of genetic tests and increasing spending on these tests are predicted to boost the segment growth. For instance, depending on the type and complexity of the test, the price of genetic testing varies from USD100 to more than USD2,000 per test. The price goes up if numerous tests are required to get a significant result or if several family members must be tested.
Global Zellweger Spectrum Disorder Market, Segmentation by Therapy
Few of the well-known market leaders in the global Zellweger spectrum disorder market that are profiled by Research Nester are Invitae Corporations, CENTOGENE N.V., GeneDX, LLC, Blueprint Genetics Oy, Siemens Healthcare Gmbh, Carestream Health, Inc., Agfa-Gevaert Group, Shimadzu Corporation, Asper Biogene LLC, Trivitron Healthcare, and others.
Do You Have Any Query Or Specific Requirement? Ask to Our Expert: https://www.researchnester.com/ask-the-analyst/rep-id-4087
Recent Developments in the Global Zellweger Spectrum Disorder Market
In July 2022, leading medical genetics company Invitae Corporations unveiled a comprehensive plan to maximize the benefits of its genetics platform, which is the best in the business.
In January 2022, the Murdoch Children's Research Institute-led study discovered that it is possible, dependable, and scalable to test babies for three uncommon genetic disorders simultaneously.
Explore Our Recent Related Reports:
Lung Biopsy Systems Market Segmentation by Product Type (Core Needle, Fine Needle Aspiration, and Surgical Biopsy Devices); by Procedure Type (Transbronchial, Thoracoscopic, and Open Biopsy); and by End-Use (Cancer Research Centers, Specialty Clinics, Hospitals, and Others) – Global Demand Analysis & Opportunity Outlook 2031 AI-based Clinical Trials Solution Providers Market Analysis by Application (Oncology, Cardiovascular Diseases, Metabolic Diseases, Neurological Disease and Others); by Clinical Trial Phase (Phase-I, Phase-II and Phase-III); and by End-User (Pharmaceutical Companies, Academic Researcher, and Others); – Global Demand Analysis & Opportunity Outlook 2022-2031 Narcotics Analgesics Market Analysis by Type (Non-Opioids, and Opioids); by Application (Pain Management, Cough Treatment, and Diarrhea); and by Administration Route (Oral, Intravenous, Rectal, Transdermal, and Topical) – Global Supply & Demand Analysis & Opportunity Outlook 2022-2031 Breast Pumps Market Analysis by Product Type (Open System, and Closed System); by Technology (Manual, Single Electric, Double Electric, and Wearable); and by End-User (Personal Use, Maternity Centers, and Hospitals) – Global Supply & Demand Analysis & Opportunity Outlook 2022-2031 COPD Therapeutics Market Analysis by Drug Class (Bronchodilators, Steroids, Phosphodiesterase-4 Inhibitors, Theophylline, Antibiotics, Oral, and Inhalation); by Type (Chronic Bronchitis, and Emphysema); by Age Group (Below 5 years, 5-14 years, 15-60 years, and Above 60 years); and by End User (Hospitals, Private Clinics, and Outpatient Departments) – Global Supply & Demand Analysis & Opportunity Outlook 2022-2031
Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.
Contact for more Info: AJ Daniel Email: info@researchnester.com U.S. Phone: +1 646 586 9123 U.K. Phone: +44 203 608 5919
For More Update Follow: - LinkedIn | Twitter | Facebook | Xing
As we close in on the final quarter of 2022, investors are looking for an answer to one question: was June’s low the bottom for stocks, or do they have more room to fall? It’s a serious question, and there may be no easy answer. Markets are facing a series of headwinds, from the high inflation and rising interest rates that we’ve grown familiar with to an increasingly strong dollar that will put pressure on the upcoming Q3 earnings. Weighing in on current conditions from Charles Schwab, the $8 t
Nursing homes and debt collectors are billing and suing long-term-care residents’ family members and friends, demanding payments for debts these individuals don’t legally owe, consumer attorneys and federal regulators are claiming. Under federal law, nursing homes participating in Medicare and Medicaid can’t make such provisions a condition of admission or continued stay in the facility.
Nio (NYSE: NIO) reported increasing losses in its second-quarter earnings report this week, but investors are shrugging that off, sending shares soaring Friday morning. Although its profit margins have been on a downward trend, new models being launched could turn that around in the coming years. Consumer prices in China increased at a slower pace than many expected in August, and producer inflation sank to the lowest level since February 2021, reports Reuters.
The Facebook and Instagram owner's share price zoomed more than 4% higher on Friday, as investors bid the company up on news that it had disbanded one of its teams. Thursday afternoon, The Wall Street Journal reported that Meta had dissolved the Responsible Innovation (RI) unit at the company. This was the team that kept an eye on the ethics of its products and services, which also include messaging app WhatsApp in addition to Facebook and Instagram.
Berkshire Hathaway is on pace to collect $6.07 billion in dividend income over the next 12 months. Just five holdings will account for 71% of total payouts.
Advanced Micro Devices, Inc. stock is trending on the Yahoo Finance Platform. Here is a visualization of $AMD performance over time, how that performance compares to the wider industry, and analyst projections for the current quarter.Check out the ticker page here.
The S&P 500 is on again, off again all year. But investors clearly have a "buy list" of stocks they want to own when the rally looks real.
A strong bearish trend defined the markets in the first half of the year; since then, the key point has been volatility. Stocks hit a bottom back in June, when the S&P 500 dropped into the 3,600s. That has proven to be a support level in the last two months, and at least one strategist believes that the market won’t be testing those lows again this year. JPMorgan's Jason Hunter believes that inflation may have peaked, and that the upcoming CPI report will provide additional evidence of that. “We
In this article, we will look at 10 stocks that Jim Cramer is talking about in September. If you want to explore more stocks that journalist investor, Jim Cramer, is talking about in September, you can also take a look at Jim Cramer is Talking About These 5 Stocks in September. Jim Cramer has acquired […]
Peloton Interactive (NASDAQ: PTON) shares beat the market on Friday as the stock gained 11% by 1 p.m. ET compared to a 1.2% increase in the S&P 500. Shares have been reeling in recent months as Peloton struggled to boost sales of its exercise platforms or membership subscriptions to its services.
The Dow Jones jumped as the rally gained strength. Tesla stock surged as Elon Musk eyed a new move. A Warren Buffett stock impressed.
It's time to be extra picky.
AT&T income-hungry shareholders should have seen it coming. In April last year, a month before announcing the spinoff of its media division to shareholders in the form of shares of a 71% stake in the newly created Warner Bros. Discovery Chief Executive Officer John Stankey assured investors that “our deliberate capital-allocation plan allowed us to invest and sustain our dividend at current levels, which we believe is attractive.” AT&T’s eventual failure to raise the dividend in 2021 broke a 34-year streak and saw it booted out of the vaunted S&P 500 Dividend Aristocrats Index.
See how to gauge demand and strength in Apple, Nasdaq and other stocks on the latest list of new buys by the best mutual funds.
Gary Gensler had strong words for the crypto industry in a Thursday speech, telling an audience of lawyers that the "vast majority" of the nearly 10,000 existing crypto tokens are securities.
Immunocore Holdings plc (NASDAQ: IMCR) released initial Phase 1 data for the first off-the-shelf ImmTAC targeting PRAME, demonstrating that IMC-F106C is well tolerated and resulted in durable responses across multiple solid tumor types. Fifty-five patients have been treated across ten dose cohorts. IMC-F106C was well-tolerated, with treatment-related adverse events that were manageable and consistent with the mechanism of action. In the clinically active dose cohorts, durable partial responses (
Annaly Capital Management (NLY) closed at $6.65 in the latest trading session, marking a -0.15% move from the prior day.
Investors are seeing higher growth potential for QuantumScape's battery cell technology after an interesting EV industry development.
Wall Street firm BofA Securities on Friday identified seven semiconductor stocks that it believes can withstand the current market downturn.
Shares of Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) climbed 160.4% this week, according to data from S&P Global Intelligence. The stock closed at $14.90 last Friday and then opened this Tuesday at $12.16. The stock began trading on Aug. 31 after its initial public offering (IPO).